Designs and sells healthcare apparel, including scrubs, lab coats, and under scrubs. Offers non-scrub apparel such as outerwear, activewear, and loungewear. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
The market pays 63.2× for every dollar this company earns in a year — a price that already assumes things go well.
Against companies in its own sector, it looks cheaper than 27% of them.
Analysts' average target sits 39% above today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Debt is low and cash is strong; the finances stand solid.
Clearly below the class average.
Sales are growing strongly for its sector.
The stock has been running stronger than the market lately.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
An investor who bought at the very peak is down 70% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 4 years, sales grew about 11% a year on average.
There is $300.8M in the vault; even if every debt were paid off, $240.8M would remain.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
The company’s market value is 63 times its annual profit. Even a small disappointment could hit the price hard.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 27/100.
No clear buy-side message is coming from the executive floor.
On our five-subject report card, FIGS sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: FIGS is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (27/100) says the stock isn’t cheap.